NeurologyLive® Friday 5 — October 28, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Peer Exchange: Resources for Sleep Disorders

In this NeurologyLive^® Peer Exchange, sleep experts C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.

2: Ocrelizumab Shows No Effect on Pregnancy and Infant Outcomes

Using a cohort of more than 2000 pregnancies, the data, presented at the 2022 ECTRIMS Congress, showed an extremely rare number of major congenital anomalies while on ocrelizumab, as most patients underwent live birth with no issue.

3: NeuroVoices: Stuart Silverman, MD, on the Significance of the Phase 3 FENhance Study of BTK Inhibitor Fenebrutinib

In the latest edition of our in-depth Q&A series, the neurologist at Allegheny Health Network’s Neuroscience Institute provided perspective on a new phase 3 trial assessing fenebrutinib, an investigational BTK inhibitor for relapsing multiple sclerosis.

4: Inadequate Sleep Related to Neurocognitive Difficulties for Children With Insomnia

Fan Nils Yang, PhD, postdoctoral researcher, University of Maryland, provides greater detail on the observational cohort study he did with colleagues, where they identified a link between neurocognitive function in children and insomnia.

5: Peer Exchange: Health Care Utilization Rates Among Patients With NMOSD

Experts in neurology including Michael Levy, MD, PhD; Mitzi Williams, MD, and others, share their experiences with how patients with NMOSD are utilizing health care, and helping patients achieve optimal care.

—————————————————